Kuros to conduct Phase 2a trial in spinal fusion, comparing Fibrin-PTH to autograftPrimary endpoint is radiographic interbody fusion at 12 months SCHLIEREN (ZURICH), Switzerland, Sept. 03, 2019 (GLOBE NEWSWIRE) — Kuros Biosciences, a leader in next generation bone graft technologies, today announces that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application …